The XRP Ledger Foundation has outlined 24 proposed and approved protocol upgrades for 2027, estimating implementation costs up to $5.74 million excluding development labor. Key features include collateralized lending, perpetual futures, smart contracts, and enhanced institutional financial tools, aiming to expand XRP Ledger's capabilities in decentralized finance. Only two amendments are approved so far, with the rest requiring further development and governance decisions. The roadmap highlights significant security audits and compatibility updates, but does not guarantee all features will launch within 2027.
The XRP Ledger Foundation's 2027 upgrade plans provide context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Nov 07, 2026 22:02 WIB: of 50 priced major cryptocurrencies, 12 rose and 37 fell today. Notable movers include SXP (Solar) down 46.27% at Rp37, ONE (Harmony) up 30.40% at Rp37 with a 63% sell order activity, and BAL (Balancer) up 11.14% at Rp16.297. The most notable figure is SXP's 46.27% decline.
Shiba Inu (SHIB) closed October at $0.00000468, down 18.7% for the month and 53.3% from November 1, 2025. In Germany, the one-year holding period for tax-free sales expires on November 2, 2026, meaning losses on SHIB bought on November 1, 2025, can n...
China's central bank declared Solana's promotion in Shanghai illegal, halting the Solana Accelerate China 2026 tour and investigating involved Chinese service providers. Despite this, Solana's price remains steady around $90, just above its 200-day m...
Fair Isaac Corporation (FICO) is rated as a Hold due to regulatory risks that threaten its pricing power and volume in mortgage credit scoring. While Q4 FY2026 showed strong free cash flow, much of it came from mortgage price hikes that may not be su...
Shares of Taiwan Semiconductor Manufacturing Company (TSMC) rose 6.26% after reports that it might begin producing vertically stacked DRAM memory chips for Nvidia, its top customer. Neither company has confirmed the plans, and TSMC has not announced ...
Johnson & Johnson announced positive Phase 3 trial results for ICOTYDE (icotrokinra), an oral peptide targeting IL-23R, in treating biologic-naïve adults with active psoriatic arthritis. At 16 weeks, 58% of patients achieved ACR20 response versus 41%...
